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Abstract
Introduction National clinical practice guidelines have
recommended specific empiric antimicrobial regimes for
patients with severe community-acquired pneumonia. However,
evidence confirming improved mortality with many of these
regimes is lacking. Our aim was to determine the association
between the empiric use of a β-lactam with fluoroquinolone,
compared with other recommended antimicrobial therapies, and
mortality in patients hospitalized with severe community-
acquired pneumonia.
Methods A retrospective observational study was conducted at
two tertiary teaching hospitals. Eligible subjects were admitted
with a diagnosis of community-acquired pneumonia and had a
chest X-ray and a discharge ICD-9 diagnosis consistent with
this. Subjects were excluded if they received 'comfort measures
only' during the admission, had been transferred from another
acute care hospital, did not meet criteria for severe pneumonia,
or were treated with non-guideline-concordant antibiotics. A
multivariable logistic regression model was used to assess the
association between 30-day mortality and the use of a β-lactam
antibiotic with a fluoroquinolone compared with other guideline-
concordant therapies, after adjustment for potential
confounders including a propensity score.
Results Data were abstracted on 172 subjects at the two
hospitals. The mean age was 63.5 years (SD 15.0). The
population was 88% male; 91% were admitted through the
emergency department and 62% were admitted to the intensive
care unit within the first 24 hours after admission. Mortality was
19.8% at 30 days. After adjustment for potential confounders
the use of a β-lactam with a fluoroquinolone (odds ratio 2.71,
95% confidence interval 1.2 to 6.1) was associated with
increased mortality.
Conclusion The use of initial empiric antimicrobial therapy with
a β-lactam and a fluoroquinolone was associated with increased
short-term mortality for patients with severe pneumonia in
comparison with other guideline-concordant antimicrobial
regimes. Further research is needed to determine the range of
appropriate empiric antimicrobial therapies for patients with
severe community-acquired pneumonia.
Introduction
Community-acquired pneumonia is the seventh leading cause
of death in the USA and is the leading infectious cause of
death [1]. Although mortality dropped precipitously with the
advent of antimicrobial therapy, since 1950 mortality has grad-
ually increased [2].Critical Care    Vol 10 No 1    Mortensen et al.
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Because of this substantial mortality, numerous societies,
including the American Thoracic Society, the Infectious Dis-
eases Society of America, and the British Thoracic Society,
have published clinical practice guidelines for community-
acquired pneumonia [3-9]. Although some of the content of
these clinical practice guidelines is evidence-based, limited
evidence is available to support many of the recommendations
regarding antimicrobial therapy for patients with community-
acquired pneumonia. Previous studies have suggested that
the empiric use of β-lactams alone is associated with
increased mortality, and that the use of macrolides for patients
with community-acquired pneumonia is associated with
improved outcomes [10-15]. However, few published studies
have examined the combination of a β-lactam plus fluoroqui-
nolone for patients hospitalized with severe community-
acquired pneumonia, and all have had limited ability to assess
the impact of this therapy [10,13,16].
The aim of this study was to assess whether the empiric use
of a β-lactam with a fluoroquinolone, compared with other
guideline-concordant antimicrobial therapies, has similar 30-
day mortality for patients hospitalized with severe community-
acquired pneumonia.
Methods
This is a retrospective cohort study of patients hospitalized
with community-acquired pneumonia at two academic tertiary
care hospitals in San Antonio, TX. Both hospitals are teaching
affiliates of the University of Texas Health Science Center at
San Antonio. The Institutional Review Board of the University
of Texas Health Science Center at San Antonio approved the
research protocol with exempt status.
Study sites/inclusion and exclusion criteria
We identified all patients admitted to the study hospitals
between 1 January 1999 and 1 December 2002 with a pri-
mary discharge diagnosis of pneumonia (ICD-9 codes 480.0
to 483.99 or 485 to 487.0) or secondary discharge diagnosis
of pneumonia with a primary diagnosis of respiratory failure
(518.81) or sepsis (038.xx). Subjects were included if they ful-
filled the following criteria: first, they were greater than 18
years of age; second, they had an admission diagnosis of com-
munity-acquired pneumonia; third, they had a radiographically
confirmed infiltrate or other finding consistent with community-
acquired pneumonia on chest X-ray or computerized tomogra-
phy obtained within 24 hours of admission; and fourth, they
met criteria for severe community-acquired pneumonia either
by being in pneumonia severity index class V, meeting Ameri-
can Thoracic Society criteria for severe pneumonia, or being
hospitalized in the intensive care unit in the first 24 hours after
presentation [6,17].
Exclusion criteria included the following: first, discharge from
an acute care facility within 14 days of admission; second,
transfer after being admitted to another acute care hospital;
third, receiving 'comfort measures only' during the admission;
and fourth, receiving a non-guideline-concordant antibiotic
within the first 48 hours of admission. If a subject was admitted
more than once during the study period, only the first hospital-
ization was abstracted.
Data abstraction
Chart review data included demographics, comorbid condi-
tions, physical examination findings, laboratory data, and chest
radiograph reports. In addition, data on important processes of
care measures for patients hospitalized with community-
acquired pneumonia were also abstracted: first dose of antibi-
otics within four hours of admission, collection of blood cul-
tures before antibiotic administration and in the first 24 hours,
and measurement of oxygen saturation within 24 hours of
presentation [18].
Mortality was assessed with information from the Texas
Department of Health and the Department of Veteran Affairs
clinical database. Mortality status was assessed up to the end
of December 2002.
Antimicrobial therapy
We obtained information on all antimicrobial therapies given
within the first 48 hours of admission. Antimicrobial regimes
considered guideline-concordant included, first, β-lactam with
a macrolide or anti-pneumococcal fluoroquinolone, and sec-
ond, anti-pneumococcal fluoroquinolone with clindamycin,
vancomycin, or an aminoglycoside (for patients allergic to pen-
icillin) [6,7]. Antibiotics classified as β-lactams included
cefuroxime, ceftriaxone, cefotaxime, cefepime, ampicillin-sul-
bactam, ampicillin (high dose), piperacillin-tazobactam, imi-
penem-cilastatin, and meropenem. Antibiotics classified as
anti-pneumococcal fluoroquinolones included levofloxacin,
gatifloxacin, and moxifloxacin, and antibiotics classified as
macrolides included erythromycin, clarithromycin, and azithro-
mycin. For a patient to be classified as having received a
β-lactam plus macrolide, or a β-lactam plus fluoroquinolone,
they would have had to receive only those two antibiotics.
Patients receiving more than two antibiotics, and who received
at minimum a combination that was considered guideline con-
cordant, were classified as having received other guideline-
concordant regimes.
Risk adjustment
The pneumonia severity index was used to assess the severity
of illness at presentation [17]. The pneumonia severity index is
a validated prediction rule for 30-day mortality in patients with
community-acquired pneumonia. This rule is based on three
demographic characteristics, five comorbid illnesses, five
physical examination findings, and seven laboratory and radio-
graphic findings from the time of presentation. Patients are
classified into five risk classes with 30-day mortality ranging
from 0.1% for class I to 27% for class V for patients enrolledAvailable online http://ccforum.com/content/10/1/R8
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Table 1
Subject demographic and clinical characteristics by 30-day mortality
Variable 30-day mortality p
Alive (n = 138) Dead (n = 34)
Age (years) 63.9 ± 16 61.8 ± 14 0.2
Men 123 (90) 27 (79) 0.1
Nursing home resident 14 (10) 4 (11) 0.7
Emergency department admission 126 (91) 30 (88) 0.6
Admitted to intensive care =24 hours 82 (59) 24 (71) 0.6
Mechanical ventilation 52 (37) 3 (8) <0.001
Pre-existing comorbid conditions
Congestive heart failure 36 (26) 5 (15) 0.2
Chronic pulmonary disease 45 (33) 8 (24) 0.3
History of stroke 30 (22) 4 (12) 0.2
Chronic liver disease 13 (9) 6 (18) 0.17
History of malignancy 13 (9) 11 (32) 0.001
Renal insufficiency 4 (3) 0 0.3
History, physical, laboratory, and radiographic data
Altered mental status 33 (24) 9 (26) 0.8
Respiratory rate >30 per minute 29 (21) 8 (24) 0.7
Systolic blood pressure <90 mmHg 6 (4) 1 (3) 0.7
Heart rate >125 per minute 29 (21) 14 (41) 0.015
Temperature <95°C or >104°C 7 (5) 2 (6) 0.8
Arterial pH <7.35 25 (18) 11 (32) 0.07
Arterial oxygenation <90% 52 (38) 16 (47) 0.3
Hematocrit <30% 21 (15) 2 (6) 0.15
Blood urea nitrogen >30 mg/dl 58 (42) 15 (44) 0.8
Serum glucose >250 mg/dl 21 (15) 3 (8) 0.3
Serum sodium <130 meq/l 30 (22) 8 (24) 0.8
Pleural effusion 48 (35) 17 (50) 0.1
Multilobar infiltrates 64 (47) 18 (52) 0.5
Pneumonia severity index
Class I to III 34 (25) 6 (18)
Class IV 40 (29) 8 (24)
Class V 64 (46) 20 (58) 0.4
Processes of care
Initial antibiotics within 4 hours 46 (30) 10 (29) 0.7
Blood cultures prior to antibiotics 110 (79) 29 (85) 0.45
Oxygenation assessed =24 hours 120 (87) 30 (88) 0.8
Data are presented as number (%) or mean ± SD.Critical Care    Vol 10 No 1    Mortensen et al.
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Table 2
Subject demographic and clinical characteristics by use of a β-lactam plus fluoroquinolone versus non-use
Variable β-lactam plus fluoroquinolone p
Use (n = 50) Non-use (n = 122)
Age (years) 62.9 ± 14 63.8 +/- 16 0.4
Men 44 (88) 106 (87) 0.9
Nursing home resident 10 (20) 8 (7) 0.009
Emergency department admission 46 (92) 110 (90) 0.7
Admitted to intensive care =24 hours 37 (74) 69 (57) 0.03
Mechanical ventilation 21 (38) 34 (28) 0.08
Pre-existing comorbid conditions
Congestive heart failure 10 (20) 31 (25) 0.04
Chronic pulmonary disease 18 (36) 35 (28) 0.3
History of stroke 12 (24) 22 (18) 0.4
Chronic liver disease 6 (12) 13 (10) 0.8
History of malignancy 6 (12) 18 (15) 0.6
Renal insufficiency 11 (22) 25 (20) 0.8
History, physical, laboratory, and radiographic data
Altered mental status 13 (26) 29 (24) 0.8
Respiratory rate >30 per minute 12 (24) 25 (20) 0.6
Systolic blood pressure <90 mmHg 1 (2) 6 (5) 0.4
Heart rate >125 per minute 17 (34) 26 (21) 0.08
Temperature <95°C or >104°C 5 (10) 4 (3) 0.07
Arterial pH <7.35 14 (28) 22 (18) 0.15
Arterial oxygenation <90% 15 (30) 53 (43) 0.1
Hematocrit <30% 3 (6) 20 (16) 0.07
Blood urea nitrogen >30 mg/dl 24 (48) 49 (40) 0.3
Serum glucose >250 mg/dl 6 (12) 18 (15) 0.6
Serum sodium <130 meq/l 19 (20) 19 (24) 0.6
Pleural effusion 20 (40) 45 (37) 0.7
Multi-lobar infiltrates 24 (48) 58 (48) 0.9
Pneumonia severity index
Class I to III 13 (26) 27 (22)
Class IV 14 (28) 34 (28)
Class V 23 (46) 61 (50) 0.8
Processes of care
Initial antibiotics within 4 hours 13 (26) 43 (35) 0.4
Blood cultures prior to antibiotics 41 (82) 98 (80) 0.8
Oxygenation assessed =24 hours 42 (84) 108 (89) 0.4
Data are presented as number (%) or mean ± SD.Available online http://ccforum.com/content/10/1/R8
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in the original Patient Outcomes Research Team cohort study
[17].
Outcome
We used 30-day mortality as the outcome for this study. Pre-
vious research has demonstrated that 30-day mortality is due
primarily to the community-acquired pneumonia rather than
other co-existing co-morbid conditions [19,20]. Therefore by
using 30-day mortality as our outcome we are able to examine
the effect of different antimicrobial combinations on primarily
pneumonia-related mortality.
Statistical analyses
Univariate statistics were used to test the association of soci-
odemographic and clinical characteristics with all-cause 30-
day mortality. Categorical variables were analyzed with the χ2
test and continuous variables were analyzed with Student's t
test.
A propensity score technique was used to balance covariates
associated with antimicrobial therapy between groups [21-
23]. The propensity score was derived from a logistic regres-
sion model. A dichotomous indicator variable indexing whether
a patient received a β-lactam and fluoroquinolone was our pre-
dictor variable. To determine which covariates to include in the
model we examined the univariate associations of β-lactam
plus fluoroquinolone use with demographic and clinical char-
acteristics, and included those variables that were statistically
significant. In addition we included variables that we thought a
priori would be associated with the use of different antimicro-
bial combinations. The covariates used in the propensity score
model were pneumonia severity index, use of mechanical ven-
tilation, admission through the emergency department, initial
antibiotics within four hours, and admission to the intensive
care unit within 24 hours of admission.
We used logistic regression to assess the impact of empiric
antimicrobial therapy with a β-lactam plus fluoroquinolone on
30-day mortality. Covariates included in the model were the
use of a β-lactam with fluoroquinolone and an ordered cate-
gorical variable based on quartile stratification on the propen-
sity score. Model fit was assessed with the Hosmer–
Lemeshow goodness-of-fit test [24]. Interactions were
assessed with cross-product terms. No interactions were sta-
tistically significant, so none of the interaction terms were left
in the final model.
We used a Cox proportional hazard model to estimate, and
graph, the baseline survivor functions after adjusting for the
propensity score.
All analyses were performed with STATA version 8 (Stata Cor-
poration, College Station, TX, USA).
Results
Data were abstracted on 172 patients at the two hospitals
(Table 1). The mean age was 63.5 years (SD 15). The popula-
tion was 88% male; 91% were admitted through the emer-
gency department and 62% were admitted to the intensive
care unit within the first 24 hours after admission. Mortality
was 19.8% at 30 days. For community-acquired pneumonia-
related processes of care, 33% received the initial dose of
antibiotics within four hours of presentation and a further 58%
received the initial antibiotic dose within eight hours, 81% of
patients had blood cultures obtained within 24 hours and
before the initial dose of antibiotics, and oxygenation was
assessed at presentation in 87%.
The most common empiric antibiotic combinations used in this
sample were ceftriaxone and azithromycin in 26%, piperacillin-
tazobactam and levofloxacin in 12%, piperacillin-tazobactam
and azithromycin in 8%, cefotaxime and azithromycin in 7%,
ceftriaxone and levofloxacin in 7%, piperacillin-tazobactam
and gatifloxacin in 5%, and ceftriaxone and gatifloxacin in
3.5%.
For subjects who received a β-lactam with fluoroquinolone,
30-day mortality was 30%, (n = 15 of 50), which was signifi-
cantly higher than for patients receiving any other guideline
concordant antimicrobial combination (p = 0.03). For patients
who received a β-lactam with macrolides, 30-day mortality was
17.2% (15 of 87) and for other guideline-concordant antibiotic
regimes mortality was 11.4% (4 of 35). When stratified by
pneumonia severity index risk class, 30-day mortality was 30%
(4 of 13) for patients who received a β-lactam with a fluoroqui-
nolone, compared with 7.4% (2 of 27) for other antibiotic
regimes in pneumonia severity index classes I to III, 29% (4 of
14) compared with 12% (4 of 34) in class IV, and 30% (7 of
23) compared with 21% (13 of 61) in class V. Table 2 shows
the pneumonia severity index, components of the pneumonia
Figure 1
Proportion of surviving patients hospitalized with severe community- acquired pneumonia by antibiotics received (p = 0.004) Proportion of surviving patients hospitalized with severe community-
acquired pneumonia by antibiotics received (p = 0.004).Critical Care    Vol 10 No 1    Mortensen et al.
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severity index, and processes of care by β-lactam with a fluor-
oquinolone in comparison with other antimicrobial
combinations.
Figure 1 demonstrates the association of the use of a β-lactam
plus a fluoroquinolone, compared with other guideline-con-
cordant therapies, with 30-day mortality. This survival graph
demonstrates that there was a significant difference
(p = 0.004) in 30-day mortality between patients who
received β-lactams plus fluoroquinolones and patients who
received other guideline-concordant antimicrobial therapies.
In this cohort, 41 patients had organisms identified from blood
cultures, sputum cultures, or from Legionella studies including
sputum direct fluorescence antibody or urinary antigen studies
(Table 3). The most common organisms identified were Strep-
tococcus pneumoniae in 15 isolates and Staphylococcus
aureus in 10. As regards resistance rates of Streptococcus
pneumoniae in our sample, 3 of 15 isolates were resistant to
penicillin and 2 of 15 were resistant to fluoroquinolones.
In the multivariable analysis, after adjustment for potential con-
founders with the propensity score, the use of a β-lactam with
a fluoroquinolone (odds ratio 2.71, 95% confidence interval
1.2 to 6.1) was significantly associated with increased 30-day
mortality. Table 4 shows the results of the multivariable regres-
sion model.
Discussion
Community-acquired pneumonia continues to be an acute
medical problem, with substantial mortality and morbidity.
Although our study supports many of the antimicrobial regimes
suggested by the Infectious Diseases Society of America and
American Thoracic Society guidelines, our study calls into
question the empiric use of the antimicrobial combination of a
β-lactam plus a fluoroquinolone for patients hospitalized with
severe community-acquired pneumonia.
Our results strengthen the previous body of research address-
ing what antimicrobial therapies are appropriate for patients
with severe community-acquired pneumonia. Several previous
studies have found that the use of a β-lactam plus a macrolide
is associated with significantly lower mortality [10-13,25].
Several studies have demonstrated that monotherapy with
β-lactam is associated with worse outcomes, including
increased mortality and increased length of stay [11-
13,26,27]. Several other studies have demonstrated that the
use of empiric antimicrobial therapy that is concordant with
national guidelines is associated with decreased mortality
[12,28,29]. However, few studies have examined the combi-
nation of β-lactam antimicrobials with fluoroquinolones in com-
parison with other guideline-concordant strategies
[10,13,16], and these studies found no significant difference
between the use of a β-lactams with fluoroquinolones and
other combinations. However, these studies had significant
limitations including a lack of multivariate analysis and too few
subjects to be able to examine this antimicrobial combination.
It is unclear why the combination of a β-lactam with a fluoro-
quinolone should result in significantly higher mortality than
other antimicrobials. It is unlikely that there is a significant dif-
ference in bacterial coverage. However, because of our low
rate of positive cultures we are unable to examine whether
there was significant antimicrobial resistance. Previous stud-
ies have demonstrated that macrolides have significant anti-
inflammatory effects [30-33] and this might be the explanation
for our results. For example, there is a substantial body of
research that demonstrates that elevated cytokine levels are
associated with septic shock or acute respiratory distress syn-
drome [34-37]. In addition many of the negative prognostic
factors for patients with community-acquired pneumonia, such
as fever, leukopenia, hypoalbuminemia, and hypotension, are
med iated  b y individual cytok ines [36,38-4 0]. It is  therefore
plausible that this anti-inflammatory effect is most pronounced
in this population, who would have a higher level of serum
cytokines than patients with less severe cases of pneumonia.
We therefore find it unlikely that the effect on mortality is due
to the specific combination of the β-lactam plus fluoroqui-
nolone. Rather, our hypothesis is that regimes that contain
macrolides have significant protective effects for patients with
pneumonia.
Table 3
Etiologies of severe community-acquired pneumonia
Microorganisms Number (n = 41)
Streptococcus pneumoniae 15
Staphylococcus aureus 10
Pseudomonas aeruginosa 2
Haemophilus influenzae 7
Enterobacteriaceaa 3
Miscellaneousb 2
Other Gram-positive coccic 2
aIncluding Escherichia coli, Klebsiella pneumoniae, Klebsiella 
oxytoca, and Proteus mirabilis; bAcinetobacter species, Aspergillus 
species, and Haemophilus parainfluenzae; cincluding Enterococcus 
species and Streptococcus species.
Table 4
Results of multivariable logistic regression model
Variable β 
coefficient
SEM 95% CI p
Propensity score -0.423 0.183 -0.78 to -0.65 0.02
Use of β-lactam plus 
fluoroquinolone
0.9985 0.413 0.19 to 1.81 0.016
Intercept -1.15 0.323 -1.79 to -0.519 <0.001
CI, confidence interval.Available online http://ccforum.com/content/10/1/R8
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Our study has several limitations that should be acknowl-
edged. First, it was a retrospective cohort study, and inherent
problems related to this design include ascertainment bias.
However, we do not feel that this study has problems with
ascertainment bias because our method used discharge diag-
nosis ICD-9 codes to identify patients. Second, our sample
was predominantly male owing to the inclusion of a Depart-
ment of Veterans Affairs hospital and it is possible, but unlikely,
that females might have a different responsiveness to antibiot-
ics from that of males. Third, we were unable to collect infor-
mation on cause of death or re-hospitalizations on this cohort,
so we were unable to examine these outcomes. Fourth, we
collected information on the use of mechanical ventilation
within the first 24 hours only, so we may have missed patients
who required mechanical ventilation after that. Finally, as in any
non-experimental study, we are unable to state conclusively
that the empiric use of a β-lactam with a fluoroquinolone is the
cause of increased mortality in this cohort. However, we have
no reason to believe that β-lactam alone or with fluoroquinolo-
nes is more likely to be given to patients who present with
more severe illness. In addition, the use of the propensity
score provided a way to control for these differences in the
analysis by defining patients comparable to those with the
same score.
Conclusion
This study demonstrates an association for patients hospital-
ized with severe community-acquired pneumonia between the
empiric use of a β-lactam with a fluoroquinolone and increased
30-day mortality. These results call into question the recom-
mendation for the use of a β-lactam and fluoroquinolone in
patients with severe community-acquired pneumonia. Further
research is needed to examine this combination of antibiotics
and to determine the best antibiotic combinations for patients
hospitalized with severe community-acquired pneumonia.
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